Inheritance of Susceptibility to Malignant Blood Disorders by Jønsson, Viggo et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Inheritance of Susceptibility to Malignant Blood Disorders
Jønsson, Viggo; Awan, Haneef; Jones, Neil D.; Johannesen, Tom B.; Steig, Bjarni;
Andosdottir, Gudrid; Tjønnfjord, Geir E.
Published in:
Scientific Reports
DOI:
10.1038/s41598-019-38879-y
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Jønsson, V., Awan, H., Jones, N. D., Johannesen, T. B., Steig, B., Andosdottir, G., & Tjønnfjord, G. E. (2019).
Inheritance of Susceptibility to Malignant Blood Disorders. Scientific Reports, 9(1), [2444].
https://doi.org/10.1038/s41598-019-38879-y
Download date: 03. Feb. 2020
1Scientific RepoRts |          (2019) 9:2444  | https://doi.org/10.1038/s41598-019-38879-y
www.nature.com/scientificreports
Inheritance of susceptibility to 
Malignant Blood Disorders
Viggo Jønsson1,2, Haneef Awan2,3, Neil D. Jones4, Tom B. Johannesen5, Bjarni á steig6,7, 
Gudrid Andosdottir  7 & Geir E. Tjønnfjord1,2
Malignant blood disorders depend on heritable susceptibility genes and occur in familial aggregations. 
We suggest a model of transgenerational segregation of the susceptibility genes based on the study 
of malignant blood disorders in Norwegian and Danish families with unrelated parents, and in the 
inbred Faroese population with related parents. This model, consisting of parental genomic imprinting 
and mother-son microchimerism, can explain the male predominance in most of the diseases, the 
predominance of affected parent-offspring when parents are not related, and the different modes of 
segregation in males and females. The model displays a specific pattern in the distribution of affected 
relatives for each diagnosis, viz. a characteristic distribution in the pedigrees of family members 
with malignant blood disorder related to the proband. Three such patterns, each reflecting a specific 
transgenerational passage, were identified: (1) alterations in the number of affected relatives in 
paternal lines alone, e.g. in patterns for probands with multiple myeloma; (2) alterations in the 
number of affected relatives in both paternal and maternal lines for probands with chronic lymphocytic 
leukemia; and (3) no alterations in the numbers of male and female affected relatives in the parental 
lines, e.g. for probands with some types of malignant lymphoma.
Strong evidence supports the notion that leukemia, lymphoma, myeloma and other malignant blood disorders 
(MBD) in man constitute an entity of heritable diseases1–7, but the transgenerational transfer of the susceptibility 
to MBD is still largely unknown. Heritable susceptibility genes, so called risk genes, are necessary for the pro-
duction of tumor in the form of a mutated blood cell monoclone8,9. A repertoire of susceptibility genes for each 
diagnosis comprises one or a few specific genes combined with a number of unspecific genes that differ from 
patient to patient with the same diagnosis. Genome-wide association studies clearly show this so-called “genomic 
landscape”, e.g. in the lymphoproliferative diseases (LPD) including chronic lymphocytic leukemia (CLL), acute 
lymphoblastic leukemia (ALL), Hodgkin’s lymphoma(HL), non-Hodgkin’s lymphomas (NHL) and multiple mye-
loma (MM); and in the myeloproliferative diseases (MPD), e.g. chronic myeloid leukemia (CML), acute myelog-
enous leukemia (AML), myelofibrosis (MF), polycythemia vera (PV), and essential thrombocytosis (ET)10–17. 
There are silent bystanders within this polygenic model of susceptibility (persons having congenic susceptibility 
without developing the pathognomonic mutation), and there is a range of aggressiveness (stage of disease) in 
patients with the same diagnosis, so that low-stage diseases with weak or no symptoms are easily overlooked 
and not included in the registration of hereditary, familial MBD. Genealogical studies of MBD in families18,19, 
and large-scale screenings from cancer registries20–24 confirm a wide variety of different diagnoses within LPD 
and MPD (pleiotropy), but show no clear signs of a Mendelian or other specific pattern in the transgenerational 
transfer. Until now, no satisfactory explanation of the predominance of males has been given, e.g. in CLL. Further 
open questions concern anticipation (increased severity of malignancy down through the generations and low 
age at onset of disease)4, and sib ship birth order effect (non-random in the ages of affected siblings)25, and a pro-
nounced inconsistency with regard to co- and contravariation of diagnoses (degree of linking)23,24.
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We now describe a novel model of the segregation of susceptibility to MBD. Based on new genealogical inves-
tigations of a large number of families with MBD, we are able to recognize distinct transgenerational pathways of 
the susceptibility genes and to identify the mechanisms likely involved in the inheritance of MBD.
Material and Methods
Our study is based on a genealogical investigation of familial MBD in two groups. One group comprises 315 
patients from the inbred population of the Faroe Islands. The other group comprises 301 patients from 112 fami-
lies with MBD and unrelated parents from Norway and Denmark. In both groups, cross-checked pedigrees were 
used for study. For comparison, diagnosis frequencies were extracted from the National Cancer Registries in 
Norway and Denmark.
The Faroe Islands. Patients and diagnoses. Based on data from the Diagnostic Registry in Torshavn (capital 
of the Faroe Islands), all 341 known cases of MBD from the Faroe Islands up to December 2011 were considered 
for study. In a five year period after 2011, it was ensured that all patients with delayed diagnoses were enrolled 
after proper cross-check. Three patients failed inclusion due to lost medical record or insufficient data for the 
verification of MBD, and 23 patients failed because their exact position in the family tree was uncertain due to 
extramatrimonial relationship and unauthorized adoption. They hardly represent a selective loss, the diagnoses 
were MM 4, AML 4, ALL 3, CLL 3, NHL NOS 3, ML 3, DLBCL 2, CML 1. (Names and abbreviations of diagnoses, 
cf. Table 1) Thus, 315 patients (LPD 219, MPD 87, others 9, Table 1) were included after cross-check, comprising a 
review of the medical record and the pathologist’s SNOMED registration26 related to clinical diagnosis, laboratory 
findings, radiological assessments, symptoms and course of disease. The diagnosis of each patient was reassessed 
according to the diagnostic criteria valid at the time of diagnosis. In malignant lymphomas, for example, the 
Faroese Diagnostic Registry includes during the observation period cases according to the American Registry 
of Pathology (1934), Rappaport- (1956, 1966), Lennert- (1967), Kiel- (1974), WHO- (1976) Working- (1982) 
and Real- (1994) classifications8. Therefore, in order to obtain a common denominator for the study group, all 
included patients were grouped according to the ICD-10 diagnostic system27. NOS-diagnoses (not otherwise 
specified) have been used in 45 cases: 25 cases where the cross-check could not definitely confirm the subtype of 
NHL (NHL NOS, ICD-10 C85.9), in 15 cases in which a clear distinction between myelodysplasia (MDS) and 
other types of MPD was not ascertained (ML NOS, ICD-10 C92.9), and in five cases of lymphoid leukemia in 
elderly desolate patients who died without further diagnostic procedure (Leukemia NOS, ICD-10 C91.3–91.5).
To assure anonymity, the patients were numbered for study and no name, initials or birthplace were used so 
that no recognition from the outside was possible. For each patient, data on gender, age at entry in the study, year 
of birth, age and year of diagnosis, aliveness or age and year at death, and the birth rank order of the patient with 
the number and gender of older and younger sibs were available. There were no twins among the patients.
Families and pedigrees. The National Civil Registry in Torshavn provided the pedigrees showing the position of 
patients with MBD and their kinship with unaffected family members over 5 to 6 generations in one big family. 
Progeny Software was used for the processing and storage of the pedigrees28. The 315 included patients were 
designated Proband crude (Pc).
Population and sampling history. The genetic founders are the nearly two thousand descendants of the original 
Vikings who survived the Black Death around 1350 and reproduced themselves in about 20 generations to the 
approximately 50,000 inhabitants of today29. Before 1900 foreign settlers, mainly European traders, crafts, Danish 
priests and administrative staff, constituted a minority with minimal effect on the Faroese genome. One hundred 
years ago, the influx of foreign people, mainly from other Scandinavian countries, was only about 10 persons 
per 5 years29. The population increased from about 15,600 people in 1900 to about 49,700 in 2011, and the mean 
lifespan increased from about 45 years in 1900 to 82 years in 201129. In this inbred population, fishermen and 
sailors from abroad and later British soldiers during WW II who found a bride on the Faroe Islands most often 
brought the females home, so the Faroese genome remained largely unaffected30. The Coefficient of Inbreeding 
has never been calculated30.
The Faroese parity is unique. The mean number of live births per female was 7.4 in 1900 and 2.7 in 2011, some 
of the highest figures in Europe31. The age of the mother at first delivery was nearly the same as in Norway32 and 
in Denmark33. The late fetal death rate per 1000 live births was 11.0 on the Faroe Islands compared with 5.0 in 
Norway and 5.6 in Denmark when investigated in the late 1990s31. Estimated from data on first born singletons, 
the mean Faroese live born birth weight is significantly higher (3610 g plus/minus standard deviation 609 g) than 
that of Norway (3520 g plus/minus 574 g) and that of Denmark (3411 g plus/minus 585 g), the live born weight 
increasing with mother’s age and parity31. These data on parity and birth weight are used in the discussion of 
growth factors (cf. Discussion).
The oldest patient included was a female with CLL, born 1884. Data from the Cancer Registries in Norway and 
Denmark was used for comparison with the familial cases. Within the observation period, the diagnostic intensity 
in the main islands appears to be nearly the same as in Denmark and Norway, but lower elsewhere on the Faroe 
Islands, especially in the beginning of the period and on small, remote islands far out in the ocean with few or no 
general practitioners. Apart from the last few decades there has been no tradition for a systematic report to the 
National Danish Cancer Registry in Copenhagen, and no Faroese cancer statistic on incidence and prevalence is 
available.
All methods were carried out in accordance with relevant guidelines and regulations concerning Cancer 
Registry Data and all protocols were approved by relevant licensing authorities (cf. Acknowledgements). Further, 
all patients were included with informed consent (cf. Informed consent). Participants under the age of 18 years 
were included with informed consent from a parent or a legal guardian.
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Diagnoses Familial Diagnoses Observed Cancer Registries
ICD-10 code numbers The Faroe Islands Norway and Denmark Norway and Denmark
Lymphoproliferative 
Disorders
Pc Pc All cases recorded
Total (males, females) % Total (males, females) % % (mean)
Hodgkin’s lymphoma
HL C81 19 (12, 7) 8.7 11 (8, 3) 4.0 6
Follicular lymphoma
FL C82 14 (9, 5) 6.4 19 (13, 6) 6.9 12
Mantle cell lymphoma
MCL C82.7 0 4 (4, 0) 1.4 <1
Diffuse Non-Hodgkin’s 
lymphoma
DLBCL C83.3
34 (21, 13) 15.6 16 (9,7) 5.8 25
Peripheral T-cell lymphoma
TNHL C84 6 (2, 4) 2.7 2 (2, 0) 0.7 2
Monocytoid B-cell lymphoma
MONOC C85.7 0 4 (1, 3) 1.4 2
Non-Hodgkin lymphoma NOS
NHL NOS C85.9 25 (14, 11) 11.4 9 (4, 5) 3.3 6
Waldenström’s disease
WA C88 2 (1, 1) 0.9 8 (5, 3) 2.9 3
Multiple myeloma
MM C90 50 (31, 19) 22.8 10 (6, 4) 3.6 14
Acute lymphoblastic leukemia
ALL C91.0 16 (10, 6) 7.3 4 (2, 2) 1.4 4
Chronic lymphocytic leukemia
CLL C91.1 50 (29, 21) 22.8 181 (98, 83) 65.6 22
Prolymphocytic leukemia
PLL C91.3 2 (1, 1) 0.9 2 (0, 2) 0.7 1
Hairy cell leukemia
HCL C91.4 1 (1, 0) 0.5 1 (0, 1) 0.4 1
Large granular T-cell leukemia
LGTCL C91.7 0 3 (2, 1) 1.1 <1
Monoclonal gammopathy
MGUS D47.2 0 2 (1, 1) 0.7 2
Lymphoproliferative disease
LPD total 219 (131, 88) 100 276 (155, 121) 99.9 100
Male/Female ratio 1.5 1.3
Age at onset of disease
Years (median) 61 (58, 64) 67 (65, 69)
Birth order effect NO Patrilineal CLL, only
Myeloproliferative Disorders
Acute myeloblastic leukaemia
AML C92.0 and C92.2-9 44 (28, 16) 50.6 9 (6, 3) 37.6 70
Chronic myeloid leukemia
CML C92.1 14 (9, 5) 16.1 3 (1, 2) 12.5 15
Polycythemia vera
PV D45 4 (2, 2) 4.6 6 (4, 2) 25.0 5
Myelodysplasia
MDS D46 2 (0, 2) 2.3 2 (1, 1) 8.3 5
Myelofibrosis
MF D47.1 8 (4, 4) 9.2 1 (0, 1) 4.2 5
Essential thrombocytosis
ET D47.3 0 3 (1, 2) 12.5 <1
Myeloid leukemia, uncertain
ML NOS C92.9 15 (9, 6) 17.2 0 <1
Myeloproliferative disease
MDP total 87 (52, 35) 100 24 (13, 11) 99.9 100
Male/Female ratio 1.5 1.2
Age at onset of disease
Years (median) 54 (49, 60) 63 (59, 68)
Birth order effect NO NO
Other Malignant Disorders
Leukemia, uncertain
L NOS C95.9 7 (2, 5) 1 (1, 0)
Malignant histiocytosis
MH C96.1 2 (0, 2) 0
Table 1. Diagnoses. Comments: Pc, Proband crude, number of patients observed. NOS, not otherwise specified.
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Norway and Denmark. Patients and diagnoses. Our joint database on familial MBD has 301 patients 
(LPD 276, MPD 24, other 1) up to December 2011 (Table 1). These families were observed for new cases of MBD 
in a five year period after 2011. All diagnoses were cross-checked with reports from the pathology departments, 
medical records of the hospitals, and registrations in the national cancer registries in Norway and Denmark. The 
diagnoses were sorted according to the ICD-10 nomenclature27, in the same way as described for the Faroese 
material. All patients belonged to the genuine Scandinavian population of Norway and Denmark. There were no 
twins and no consanguinity. The first known cases of CLL, a 51-year-old man born in Norway in 1872 with CLL 
since 1923, and a 54-year-old female from Denmark, born 1864 with CLL in 1918 were included.
Families, population and sampling history. The 301 patients were extracted from 112 families in our database 
with two or more cases of MBD and unrelated parents. Several thousands of MBD patients have been screened for 
familial disease during the past two decades or more. From an overall assessment, our database is extensive in the 
sense that a large and representative number of patients have been available for the present study.
The parity in Norway and Denmark is nearly the same. The mean number of live births per female was 4.2 in 
1900 and 1.7 in 201132,33. The mean late fetal death rate per 1000 live births was 5.3 in the late 1900s31. However, 
parity comprises children born alive, stillborn, and abortions where especially the early spontaneous abortions, 
experienced as a late, strong menstruation, are practically impossible to enumerate. Taken together, about 15% of 
all pregnancies end with a miscarriage in Scandinavia32,33, but that figure too, is uncertain when estimating parity 
related to the mother in a mother-son microchimeristic scenario, because such elusive factors as the number of 
male partners and expected changes in male fertility during the observation period exert their influence.
All methods were carried out in accordance with rules and regulations concerning Cancer Registry Data (cf. 
Acknowledgements) and all patients were included with informed consent (cf. Information consent). Participants 
under the age of 18 years were included with informed consent from a parent or a legal guardian.
Statistics. Diseases. The MBD-patients observed in the Faroese family and in MBD-families from Norway 
and Denmark were compared with “a normal material” based on data from the whole population National Cancer 
Registries in Oslo34 and Copenhagen35, and from the LYFO-Registry36 (Table 1). The diagnoses observed were 
expressed in per cent of the total LPD and total MPD, respectively, and the percentages (frequencies) were used 
for comparison of the findings in the Faroese family with the families from Norway and Denmark, and for com-
parison with the normal material. Significance was accepted for P < 0.05. Sex- and age-adjusted incidences and 
prevalences would have been ideal, but these parameters are not available in the Faroese material and cannot 
reliably be constructed retrospectively as described (cf. Material and Methods, the Faroe Islands, Population and 
sampling history). Age at onset of disease in the two groups of familial MBD was described and compared by 
means of two-sided Mann-Whitney’s test.
Genealogy. Each patient with familial MBD (Table 1) was appointed Proband crude (Pc) and the number, diag-
noses and position in the pedigree of his or her affected relatives (AR) were recorded (Fig. 1, Table 2).
The pedigrees of all Faroese Pc were manually formatted into one united pedigree to describe the inbred 
family in which the AR were registered only once with ties of kinship in paternal (PA) and/or maternal (MA) 
lines (Fig. 1). The AR associated a given Pc in the united Faroese pedigree were recorded with up to five healthy 
family members between Pc and AR in vertical (parental) lines and/or in other vertical, oblique lines (uncle, 
aunt). The AR included were allocated to one of the following groups (1) AR in both patrilineal and matrilineal 
lines (PA + MA), (2) in PA only (PA), (3) in MA only (MA), or (4) entirely mixed or unknown (PA = MA), which 
means that ancestors to the proband of father’s and mother’s lines are mixed due to inbreeding to such an extent 
that their parental affiliation could not be determined (Fig. 1). In the same way, Fig. 1 also shows the parental 
affiliation added from the smaller 112 families with unrelated parents from Norway and Denmark.
A given AR was registered only once per Pc in either PA or MA, the one chosen being the one closest to the 
proband. The united pedigree with the total overview of the large, inbred Faroese family made it feasible to rule 
out double entry of a given AR to the same Pc. However, a given patient in the pedigree could act as AR to several 
Pc, especially in parts of the pedigree with many patients, viz. a high density of Pc and many shared AR. This 
explains why the total number of observed AR (Table 2) can be significantly higher than the total number of Pc 
(Table 1), both in LPD and in MPD. Data from the smaller Norwegian and Danish MBD-families shows the same 
tendency although the number of shared AR per Pc is much lower (301 Pc from 112 MBD-families) than in the 
Faroese material.
In order to expose a common pattern in the transgenerational transfer of MBD-susceptibility, the united 
Faroese pedigree was used as a master for inferential visual pattern recognition37,38 to identify the mechanism 
behind the distribution of AR and Pc. We considered all relevant mechanisms we could think of (the Mendelian 
modalities, genomic imprinting, mother-son and mother-daughter microchimerism, gene linkage etc.). There are 
four different groups of Pc-AR with different parental affiliation (Fig. 1). In order to estimate paternal and mater-
nal inheritances separately as part of the pattern recognition, a uniform, monoparental assessment of AR was 
required. Proband standard (Ps) denotes such a monoparental affiliation of AR to a given Pc. In contrast to Pc, 
Ps counts only one parental affiliation with its ARs in either patrilineal (Ps-PA) or in matrilineal (Ps-MA) lines. 
The following guidelines were used to convert Pc to Ps: Group (1), Pc having ARs in both father’s and mother’s 
lines at the same time gave rise to twice the number of Ps, one for PA and one for MA. In Group (2) and (3), the 
number of Pc was equal to Ps. Data from Group (4) was allocated to either Ps-PA or to Ps-MA based on an esti-
mation of which parental line that brought Ps and the majority of AR closest together. In other words the lowest 
number of healthy family members between Ps and AR compared in the father’s and mother’s line in the pedigree. 
Some 21 Faroese Pc (12 males and 9 females) had a very peripheral position in the pedigree so that no affected 
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predecessors could be seen. These cases of unknown parental affiliation were shared equally between Ps-PA and 
Ps-MA. The numbers of observed ARs are reported in Table 2, denoted OBS.
The number of OBS (Table 2) was compared with the expected number of AR (total, males, females), denoted 
EXP (Table 2). EXP (the null-hypothesis) was based on an equal distribution of the AR among the four groups: 
Psm-PA, Psm-MA, Psf-PA and Psf-MA, viz. 25% of OBS for each of the four groups.
The birth order effect, i.e., the rank in the sib ship by age of affected sibs, was estimated for every Pc by means 
of the Haldane Smith test25, in which the sum of rank numbers in the test sample (6A) was compared with the 
theoretical value and expressed as the 95% confidence interval (CI 95%). The Wilcoxon signed-ranks test was 
used for control, comparing the sum of positive (older) and negative (younger) rank numbers of affected sibs in 
the sib ship with zero representing the median age of all healthy and affected sibs in the sib ship.
To estimate anticipation, the number of patients in each diagnosis in the familial material (“observed”) was 
compared with the National Cancer Registry findings (“expected”) by chi-squared test.
Co- and contra variation in the Faroese material was estimated by means of a systematic comparison of AR 
per Pc, observed versus expected (chi-squared test, significance P < 0.05).
Statistical analysis was done with programming language R version 3.3 (www.r-3-3project.org).
Informed Consent. The patients were informed about the purpose of the study, that it was free to decline, 
of course, and that the investigation was approved by the Scientific Ethical Committee. Furthermore, that data 
would remain confidential and unrecognizable outside the study, and that data could be crosschecked with the 
National Cancer Registry and with the Civil Person Registry if necessary. Each patient confirmed participation by 
completing a questionnaire, approved by the National Ethical Committees.
Results
Diagnoses. The myeloproliferative disorders are more frequent in the Faroe material (28% of all MBD) than 
in the families from Norway and Denmark (8%). (Table 1) AML is predominant but with a frequency lower than 
expected when comparing with the percentage of AML reported by the whole-population Norwegian and Danish 
Cancer Registries (P < 0.05). In contrast, CML has nearly the same frequency in the families and in the cancer 
registries.
Regarding the lymphoproliferative pleiotropic diversity, CLL is increased in the Norwegian and Danish fami-
lies compared with the percentage of CLL reported by the cancer registries (P < 0.01). In contrast, the percentage 
of MM is increased on the Faroe Islands (P < 0.01) where MM is as common as CLL. A reduction of familial 
DLBCL compared with the occurrence of DLBCL in the cancer registries is confirmed in both the Norwegian 
and Danish families (P < 0.01) and in the Faroese family (P < 0.05). A near halving of FL is seen in families with 
Figure 1. Pc and Ps probands and their parental affiliation. Pc, (Proband crude, number of patients observed: 
total (males, females)). Ps, (Proband standard, number of patients according to monoparental affiliation). 
Arrow shows the conversion of Pc to Ps. PA and MA, patrilineal and matrilineal; PA = MA, mixed or uncertain 
parental affiliation; Other vertical pairs than Parent-Offspring, for example, Proband-Uncle, Proband-Aunt 
pairs. A given Pc can act in several combinations of pairs at the same time, for example in sib concordance and 
concomitantly in a Parent-Offspring pair. Therefore, the number of pairs is not half the number of patients. 
Abbreviations, diagnoses (cf. Table 1): LPD, lymphoproliferative disorders; Other LPD, T-NHL, Burkitt-NHL, 
WA, PLL and HCL; MPD, myeloproliferative disorders; Other MPD, PV, MDS, ML NOS.
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MBD (P < 0.05), even when the uncertainty related to NHL NOS is taken into account (50% united NHL, ICD-
10 C82–C85, reported by the cancer registries compared with 19.6% of the Norwegian and Danish families, and 
36.1% of the Faroese families).
Affected Relatives (mean)/Pc Affected Relatives Total (males, females) in Ps groups
m/m f/m m/f f/f Psm-PA Psm-MA Psf-PA Psf-MA Totals
LPD/HL 5.7 4.4 9.7 7.6
OBS 65(37, 28) 25(13, 12) 13(6, 7) 18(12, 6) 121(68, 53)
EXP 30(17, 13) 30(17, 13) 30(17, 13) 30(17, 13) 121(68, 53)
OBS/EXP (P) 3(3, 3) 0(0, 0) −2(−2, 0) −1(0, 0)
LPD/NHL FL 4.9 2.2 8.8 4.0
OBS 13(12, 1) 19(12, 7) 7(2, 5) 25(18, 7) 64(44, 20)
EXP 16(11, 5) 16(11, 5) 16(11, 5) 16(11, 5) 64(44, 20)
OBS/EXP (P) 0(0, 0) 0(0, 0) −1(−2, 0) 0(0, 0)
LPD/NHL DLBCL 4.7 3.9 7.6 6.3
OBS 59(32, 27) 42(23, 19) 39(24, 15) 41(20, 21) 181(99, 82)
EXP 45(25, 20) 45(25, 20) 45(25, 20) 45(25, 20) 181(99, 82)
OBS/EXP (P) 1(0, 0) 0(0, 0) 0(0, 0) 0(0, 0)
LPD/NHL NOS 5.9 3.7 7.5 4.7
OBS 28(19, 9) 37(22, 15) 39(23, 16) 30(18, 12) 134(82, 52)
EXP 34(21, 13) 34(21, 13) 34(21, 13) 34(21, 13) 134(82, 52)
OBS/EXP (P) 0(0, 0) 0(0, 0) 0(0, 0) 0(0, 0)
LPD/MM 5.8 4.3 9.5 7.0
OBS 102(63, 39) 88(46, 42) 46(23, 23) 77(48, 29) 313(180, 133)
EXP 78(45, 33) 78(45, 33) 78(45, 33) 78(45, 33) 313(180, 133)
OBS/EXP (P) 2(2, 0) 0(0, 0) −3(−3, 0) 0(0, 0)
LPD/CLL 5.0 3.2 7.0 4.5
OBS 82(53, 29) 77(51, 26) 43(19, 24) 38(23, 15) 240(146, 94)
EXP 60(37, 23) 60(37, 23) 60(37, 23) 60(37, 23) 240(146, 94)
OBS/EXP (P) 2(2, 0) 1(1, 0) −1(−2, 0) −2(−1, 0)
MM/CLL (Small sample size)
OBS 21(14, 7) 17(10, 7) 13(9, 4) 4(4, 0) 55(37, 18)
EXP 14(9, 5) 14(9, 5) 14(9, 5) 14(9, 5) 55(37, 18)
CLL/CLL (Small sample size)
OBS 15(10, 5) 14(7, 7) 12(9, 3) 10(4, 6) 51(30, 21)
EXP 13(8, 5) 13(8, 5) 13(8, 5) 13(8, 5) 51(30, 21)
LPD/ALL 3.5 1.6 5.8 2.7
OBS 19(15, 4) 10(6, 4) 7(3, 4) 15(11, 4) 51(35, 16)
EXP 13(9, 4) 13(9, 4) 13(9, 4) 13(9, 4) 51(35, 16)
OBS/EXP (P) 0(0, 0) 0(0, 0) 0(−1, 0) 0(0, 0)
LPD/other LPD (Small sample size)
OBS 11(8, 3) 4(2, 2) 25(9, 16) 12(5, 7) 52(24, 28)
EXP 13(6, 7) 13(6, 7) 13(6, 7) 13(6, 7) 52(24, 28)
LPD/LPD 5.2 3.6 7.7 5.4
OBS 382(239, 143) 299(175, 124) 219(111, 108) 256(153, 103) 1156(678, 478)
EXP 289(170, 119) 289(170, 119) 289(170, 119) 289(170, 119) 1156(678, 478)
OBS/EXP (P) 3(3, 1) 0(0, 0) −3(−3, 0) 0(0, 0)
MPD/LPD 4.0 2.7 5.9 4.0
OBS 85(60, 25) 64(40, 24) 25(7, 18) 63(34, 29) 237(141, 96)
EXP 59(34, 24) 59(34, 24) 59(34, 24) 59(34, 24) 237(141, 96)
OBS/EXP (P) 3(3, 0) 0(0, 0) −3(−3, 0) 0(0, 0)
LPD/MPD 3.2 2.4 4.7 3.6
OBS 91(54, 37) 79(44, 35) 50(21, 29) 71(45, 26) 291(164, 127)
EXP 73(41, 32) 73(41, 32) 73(41, 32) 73(41, 32) 291(164, 127)
OBS/EXP (P) 1(1, 0) 0(0, 0) −2(−2, 0) 0(0, 0)
MPD/MPD 2.8 1.7 4.2 2.5
OBS 95(66, 29) 66(45, 21) 28(10, 18) 47(27, 20) 236(148, 88)
EXP 59(37, 22) 59(37, 22) 59(37, 22) 59(37, 22) 236(148, 88)
OBS/EXP (P) 3(3, 0) 0(0, 0) −3(−3, 0) 0(0, 0)
MPD/AML 2.5 1.7 4.4 3.0
OBS 41(27, 14) 32(19, 13) 17(7, 10) 28(17, 11) 118(70, 48)
EXP 30(18, 12) 30(18, 12) 30(18, 12) 30(18, 12) 118(70, 48)
OBS/EXP (P) 1(1, 0) 0(0, 0) −1(−2, 0) 0(0, 0)
MPD/CML 3.4 2.4 6.2 4.4
OBS 21(15, 6) 12(9, 3) 8(1, 7) 12(6, 6) 53(31, 22)
EXP 13(8, 5) 13(8, 5) 13(8, 5) 13(8, 5) 53(31, 22)
OBS/EXP (P) 1(1, 0) 0(0, 0) 0(−1, 0) 0(0, 0)
MPD/other MPD 3.1 1.1 3.4 1.2
OBS 26(19, 7) 16(13, 3) 2(0, 2) 2(2, 0) 46(34, 12)
EXP 12(9, 3) 12(9, 3) 12(9, 3) 12(9, 3) 46(34, 12)
OBS/EXP (P) 3(3, 1) 0(0, 0) −2(−2, 0) −2(−1, 0)
Table 2. Affected Relatives and Proband Pc and Ps, The Faroe Islands. Comments: Abbreviations, cf. Tables 1 
and 2. m, males; f, females. OBS/EXP (P): observed versus expected (P, chi-squared test). Zero: observed not 
different from expected (P > 0.05). Positive values, observed higher than expected. Negative values, observed 
lower than expected. At the following levels: P < 0.05 score 1, P < 0.01 score 2 and P < 0.001 score 3.
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HL is increased in familial MBD, compared with the figures from the cancer registries, reporting 6% HL out of 
all LPD and 12% HL out of all malignant lymphomas (HL plus NHL) in Norway and Denmark. The Norwegian 
and Danish families showed 16.9% HL among all malignant lymphomas, and the Faroese family showed 19.4% 
(P < 0.01).
The percentage of ALL reported by the cancer registries is not significantly different from the percentage in 
the Norwegian and Danish families (P > 0.05) while in the Faroes material, the proportion of ALL is nearly twice 
as high (P < 0.01).
The Faroese material has the most pronounced signs of malignancy and anticipation, for example the highest 
frequency of ALL and the lowest frequency of some indolent lymphomas, e.g. FL, and the lowest age at onset of 
disease, LPD (P < 0.05), MPD (P < 0.01). Male patients had in general a lower mean age at onset of disease than 
female patients in both the Faroes and in the Norwegian and Danish material, LPD (P < 0.05), MPD (P < 0.01). 
The male/female ratio is higher on the Faroe Islands (P < 0.05).
A significant birth order effect is only observed in the Norwegian and Danish CLL-families related to patrilin-
eal inheritance where affected sons appeared late in the sib ship (P < 0.05).
Probands and parental affiliation. Each patient referred to in Table 1 was appointed as Proband crude 
(Pc). (Fig. 1) The positions in the pedigree of a patient’s affected relatives (AR) were counted as described in 
section “Material and Methods, Statistics, Genealogy”: PA + MA (AR in both parental lines; PA (paternal only); 
MA (maternal only); and PA = MA (mixed or uncertain). Analysis of Ps (Pc formatted into monoparental lines) 
in the inbred Faroese family showed that the number of Ps-PA and Ps-MA is not significantly different in LPD 
(P > 0.05) and MPD (P > 0.05), and that Ps-males are predominant compared with Ps-females in both in PA 
and MA (P < 0.01). Parent-offspring affected pairs are rare compared with oblique affected pairs between Ps and 
uncle, aunt, denoted “other vertical pairs”, LPD 98%, MPD 100% (P < 0.001).
In contrast, the Norwegian and Danish families with unrelated parents shows that Ps-MA is larger than Ps-PA 
(LPD: P < 0.05; MPD: same tendency with small sample sizes). In both PA and MA, parent- offspring pairs are 
predominant (P < 0.01).
Probands and affected relatives. All LPD and MPD in the Faroese material have an entirely stereotypic 
pattern where Pc-females have more AR than Pc-males (P < 0.001), and the AR/Pc ratio m/m is larger than f/m 
(P < 0.001) and m/f is larger than f/f (P < 0.001) (Table 2 to the left).
(Table 2) In AR/Ps (Table 2 to the right), OBS is the number of AR counted in the pedigree for Pc and trans-
formed into AR/Ps. EXP is the excepted ratio AR/Ps. The expected number of AR has been calculated as one 
fourth of the total observed AR equally distributed among the four Ps-groups Psm-PA, Psm-MA, Psf-PA and 
Psf-MA (cf. Material and Methods, Statistics, Genealogy). OBS and EXP were compared using chi-squared test.
AR/Ps displays three distinct patterns of distribution (PD). Each PD has a characteristic configuration of the 
probands and their affected relatives, males and females, related to the parental affiliations. (1) The most common 
PD, seen in LPD/MM, LPD/LPD, MPD/LPD, LDP/MPD, MPD/MPD, MPD/AML and MPD/CML, has in PA a 
higher number of AR-males related to Ps males and fewer AR-males related to Ps females than expected while in 
MA, the numbers of AR-males and AR-females are as expected. (2) A PD for Ps-CLL with increased male-AR to 
Ps-males in both PA and MA combined with decreased male-AR related to Ps-females in both PA and MA. This 
tendency was also seen in MM/CLL, CLL/CLL and LPD/other LPD, even though consisting of only small sample 
sizes. Finally, (3) a PD for NHL and ALL, where the numbers of AR-males and AR-females were generally not 
different from what was expected in PA and MA.
In contrast to the Faroese AR, belonging to one big family, there are 112 Norwegian and Danish families with 
a total of 301 MBD-patients, so that the mean number of MBD-patients per family is only 2.7, and the mean num-
ber of AR per Pc, (301-112)/112), is 1.7, too small for a reliable comparison with the huge numbers of AR in the 
Faroese material. However, taking data from Table 2 into account, it can be concluded that the parental affiliation 
of AR to Norwegian and Danish Ps is stronger in MA than in PA in LPD and MPD (P < 0.01), compared with an 
equal affiliation to PA and MA in the Faroese material (P > 0.05).
Co- and contravariations. All diagnoses have been systematically screened for co- and contra variation, 
comparing observed data versus expected. In HL, for example, Pc is 19 (12, 7), total (males, females), and the 
total of Pc-LPD is 219 (131, 88) (Table 1). The number of AR to HL is 121 (68, 53) (Table 2). Thus, if AR were 
equally distributed, the expected number of total AR would be 19 × 121/219 = 10.5 compared with the observed 
19 (chi-squared test = 4.90). Observed versus expected males and females were compared in the same way. 
Significant results from the Faroe Islands:
PcMM-contravariation AR: CLL.
PcMM-covariation AR: ALL, CML and ML NOS.
PcDLBCL-covariation AR: DLBCL and MM.
PcDLBCL-contravariation AR: CLL.
PcNHL NOS-covariation AR: HL and DLBCL.
PcAML-covariation AR: AML, MM and DLBCL.
PcAML- contravariation AR: CLL and ML NOS.
PcCLL-co- and contravariation AR: none.
Covariation of the same diagnosis in Pc and AR (clustering): HL, DLBCL, MM, AML.
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Discussion
New cumulative data from families with multiple cases blood disorders (MBD) reveal three patterns of the distri-
bution (PD) of the patients in the family (Table 2). Assuming that a systematic description of the mutual positions 
of the patients in the pedigree to some extent reflects the segregation of the genetic susceptibility to MBD, pattern 
recognition37,38 exposes parental genomic imprinting39 together with mother-offspring microchimerism40–44 as 
the likely mechanisms involved in the transgenerational segregation of the susceptibility genes. Figures 2 and 3 
were used to describe the interaction of these mechanisms in the conversion of the static PD into the dynamic 
operative algorithms (pathways).
Pathway 1 contains a higher number of male affected relatives (AR) related to male-Ps (proband standard) 
and fewer AR-males related to female-Ps in paternal (PA) lines than expected, and no significant changes in 
maternal (MA) lines (cf. Results, Proband and Affected Relatives, Table 2). Maternal imprinting combined with 
mother-son microchimerism can explain an increasing number of affected males with highly expressed suscepti-
bility (Fig. 2) and seems a plausible explanation of the surplus of males in LPD/MM, LPD/LPD, MP D/LPD, LDP/
MPD, MPD/MPD, MPD/AML and MPD/CML (Table 2). These PA-lines receive in addition affected males (e.g. 
IVaCF in Fig. 2) from father carriers (e.g. IIIaC) where the sons will proceed into the next generations as PA-lines 
with affected males in every generation. In contrast, affected females are produced only in every other generation 
on one line of descent with low expressive microchimeristic genomic changes, with offspring along the MA-lines 
that break up the continuous lines of AR-males available per female proband. Thus, affected females in PA-lines 
will have fewer affected males available, “spread of the AR in the pedigree”, than the affected males (Table 2).
Concomitant paternal imprinting and mother-son microchimerism (Fig. 3) of susceptibility genes from the 
genomic landscape of the diagnosis can explain the presence of affected mother-offspring pairs in a functionally 
balanced interaction between PD 1 and PD 2. A near equal number of affected males and females are produced. 
The affected males have a relatively weak expression of microchimeristic genomic changes (mixed red capital and 
red small letters) and no males have a strong expression (red capital only) like that seen in maternal imprinting. 
In other words, the microchimeristic genomic changes in males and females are more alike in MA-lines than in 
PA-lines. This can explain the non-significant difference when comparing the distribution of observed (OBS) 
males versus expected (EXP) males in MA-lines of PD 1 and pathway 1.
Pathway 2, related to CLL, has increased male-AR to male-Ps in both PA and MA-lines combined with 
decreased male-AR related to female-Ps in both PA and MA-lines (cf. Results, Proband and Affected Relatives, 
Table 2). Concomitant maternal imprinting and mother-son microchimerism is assumed to exert its action as 
described above related to PD1 and pathway 1. In CLL, however, especially in families with unrelated parents, 
affected mother-son pairs are the most frequent transgenerational combination (Fig. 1), indicating a stronger 
affinity of mother’s susceptibility to sons than to daughters. That concerns the paternal imprinting and its 
mother-son microchimerism in such a way that affected males become predominant (e.g. in the combinations 
from IIaC to IIIaC, and from IIIacG to IVacG, Fig. 3) explaining the PD 2 in MA of pathway 2. Here, the pro-
duction of affected males by paternal imprinting, restricted to MA-lines (Fig. 3), is higher (more intensive) than 
expected, viz. higher than an equal distribution of AR, expressed by assigning one fourth of the total AR to each 
Figure 2. Maternal imprinting and mother male-feto microchimeristic genomic change. Proposed model of 
the segregation of susceptibility. Maternally imprinted susceptibility genes: Black square (affected male) or 
black circle (affected female); combined black and white (carrier); white (normal person) in four generations 
(I–IV). Mother-son microchimeristic changes of susceptibility genes: red capital “A to G” (strong expression 
of susceptibility); red small letters “a to g” (weak expression of susceptibility). Capital at the same line as the 
mother (acquired microchimeristic genomic change in the mother); red capital underlined (male inducer of 
microchimerism). Anticipation can be seen as an increased microchimeristic genomic load (red letters) down 
through the generations. Manifest disease depends on a certain load of susceptibility genes, for example black 
signature (imprinted genes) and at least two red letters (microchimeristic genomic changes). Paternal (PA) lines: 
Manifest male disease accumulates e.g. in the father-son line to the left in the figure from IIIAB to IVABD and 
further on in the PA males in the next generations with highly expressed microchimeristic genomic changes 
(red capitals only). And in the PA lines of sons of carrier fathers, e.g. IVaCF and further down in the next 
generations, all with partial expression of the microchimeristic genomic changes (mixed red capital and red 
small letters). Thus, the male probands in PA lines have a greater number of male affected relatives than female 
probands, because the female probands create carriers that break up the continuous lines of affected males 
and thereby reduce the number of available affected relative males per female proband. Maternal (MA) lines: 
An equal number of carrier males and females are produced from affected females. Transgenerational lines of 
female carriers are produced in MA lines, e.g. to the right in the figure from IIIacG to IVacg and further on in 
the subsequent generations of MA.
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of the four Ps-groups Psm-PA, Psm-MA, Psf-PA and Psf-MA. That’s exactly what is seen in the distribution of 
male-AR to CLL female-Ps in MA-lines (e.g. LPD/CLL, Table 2).
Pathway 3, related to NHL and ALL (Table 2), exhibits an expected number of affected males and females in 
both PA and MA-lines, which is easily explained as a merge of Figs 2 and 3 where affected males and females have 
nearly the same microchimeristic genomic expression (A = a, B = b, C = c etc.) without predominance of affected 
males.
Figures 2 and 3 depict a situation with stronger microchimeristic genomic charge in males (red capitals) than 
in females (red small letters) but otherwise, the pathways are assumed to act in concert depending upon the 
MBD-diagnoses related to the pleiotropic susceptibility genes present in the patient (“the genomic landscape”). 
Gradual deviations from the pathways, for example in LPD/HL (Table 2), are theoretically expected in advance 
due to degrees of gene expressivity (penetrance), variations in trigger-environmental epigenetic stimuli, co- and 
contravariation, and the number and range order by age of the sons in the sib ship. By means of the AR/Pc ratios 
as a kind of control (Table 2 to the left) it is easy to see that the ratios AR/Pc-females are generally higher than AR/
Pc- males as expected when the number of affected females is lower than the number of affected males (Table 1). 
Ratios with AR males are generally higher than ratios with AR females as expected when the number of affected 
males is higher than the number of affected females (Table 1), especially in CLL8,45–48. The increased number 
of male CLL-patients has been a mystery for decades so far, there have been no evident hormonal or any other 
pathophysiological explanations.
The genetic mode of segregation in the three pathways emerged while trying to match our findings against 
all known Mendelian and non-Mendelian modalities. Parental genomic imprinting combined with mother-son 
microchimerism appeared as a comprehensive correct solution bringing about a strong match, especially when 
both maternal and paternal imprinting are combined. Maternal imprinting causes accumulation of susceptibility 
in males (Fig. 2 to the left) and the formation of female carrier lines (to the right). Paternal imprinting causes 
accumulation of susceptibility in females (Fig. 3 to the right) and the formation of male carrier lines (to the left). 
Pattern recognition suggests that one combine both mechanisms to explain the presence in the pedigrees of 
affected father-offspring lines (in Fig. 2) and affected mother-offspring lines (in Fig. 3).
The many small families with unrelated parents from Norway and Denmark with a mean of only about 3 
patients per family would never deliver such a clear PD as the Faroese with 315 patients in one family. However, 
the families from Norway and Denmark deserve attention because they support the idea of the model (Figs 2 
and 3) that the degree of tissue-type compatibility (microchimerism) is relevant. We got a better match between 
our data and mother-son microchimerism than mother-son added daughter microchimerism. That could well 
be in accordance with the fact that mother-son microchimerism is the strongest due to difference in gender (“the 
gender barrier”). Thus, affected mother-son pairs are the most frequent parent-offspring combination in families 
with unrelated parents (Fig. 1). A birth order effect late in patrilineal sib ships was only seen in male CLL with 
unrelated parents (Table 1) at that precise place where mother’s acquired and accumulated tolerance to HLA 
of the father and of the male haploloads of the sons is assumed to be highest. That, however, does not exclude a 
certain degree of mother-daughter microchimerism at the same time which may even be theoretically expected 
by powerful mother-son microchimerism49,50. Most likely so in Pathway 3, where the numbers of affected males 
and females in PA and MA are as expected. No birth order effect, nearly no affected parent-offspring pairs, and 
no sib concordance were seen in the Faroese material, where the HLA compatibility between mother-offspring 
and father is assumed to be relatively high due to consanguinity so that the microchimerism reaction is relatively 
weak. In consanguinity, the difference between maternal and paternal haploloads of the fetus may furthermore be 
evened out because both parents theoretically may confer different imprinted susceptibility, causing alterations in 
the stochastic, independent regulation of the proband49.
Figure 3. Paternal imprinting and mother male-feto microchimeristic genomic change. Proposed model of 
the segregation of susceptibility. Paternal imprinting, otherwise the same signature as for Fig. 1. Paternal lines 
(PA): An equal number of carrier males and females are produced from carrier males under the formation of a 
continuous male carrier line (to the very left in Fig. 2). Maternal lines (MA): Accumulation of manifest female 
disease, e.g. in the mother-daughter line to the right in the figure from generation IIaC to IIIacG to IVacg and 
further on to the females in MA lines in the next generations. And in the MA lines of females of carrier mothers, 
e.g. IVabe and down with the females in MA lines in the subsequent generations, all with predominantly low 
expression of microchimeristic genomic changes (mainly small red letters). All affected males are produced in 
MA lines, and the affected males have in general a stronger expression of microchimeristic genomic changes 
than the affected females.
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The statistical power of our findings can be discussed, especially since the patients have been sorted up in 
many diagnostic subsets and transgenerational groups. Compared with thousands of investigated patients with 
MBD from cancer registries and from genome-wide association studies, our patients represent small sample 
sizes. However, our findings get strength from being systematically cross-checked over several generations. This 
is especially true of the Faroese material, as far as we know the largest consanguineous population with MBD 
described up to now.
It is not really surprising to see parental genomic imprinting and microchimeristic genomic changes as the 
predicted mechanisms of the model, because both are well known to be related to MBD.
Parental genomic imprinting is seen in the segregation of mammalian growth factor genes50,51, where subsets 
of genes required for the development are expressed at specific stages of life and in specific tissues from only one 
chromosome copy, depending upon the parental origin of that chromosome copy49–52. Parental genomic imprint-
ing has earlier been discussed as a possible mechanism behind the non-Mendelian genomic output in CLL53. A 
common feature in the segregation of this group of genomic imprinted genes is a pronounced different outcome 
in paternal and in maternal imprinting. One classic example is the Prader-Willi and Angelman syndromes54, 
caused by a partial deletion of chromosome 15 in most of the cases. If a fetus receives the chromosome with the 
deletion from the father, and the inactivated, imprinted copy of the gene from the mother (maternal imprint-
ing), the fetus will have Prader-Willi syndrome. In contrast, a fetus receiving the partially deleted chromosome 
from the mother and the imprinted gene from the father (paternal imprinting) will have Angelman syndrome. 
Similarly, MBD is a syndrome closely related to the growth of monoclonal hematopoietic cells. Women with 
CLL45,46 or NHL55 have in general a better prognosis than male patients, including a better response to treatment 
with less toxicity and generally a higher age at onset of disease. These differences in MBD between the sexes, oth-
erwise not definitely explained, could be seen as a different inheritance of susceptibility according to pathway 1 
to 3. All known systems of meiotic drive (Non-Mendelian segregation) cause segregation ratios that are different 
between the sexes49–52.
The relationship between alterations in growth factors and MBD is also seen, most likely, from the combined 
data on the high frequency of MBD on the Faroe Islands, the high birthweight and the high rate of miscarriages and 
stillborn (Cf. Material and Methods, “the Faroe Islands, Families and Sampling History”)29–31. A relationship between 
development of MBD (ALL is the most studied) and a high body weight of the patient as newborn has been shown 
in other studies as well as an increased frequency of miscarriages and abortions in mothers to MBD patients56,57.
In such systems of interacting genes, modifier genes may invade the system during the evolution50,52,58,59. 
Therefore, a modifier to our model was theoretically expected. Microchimerism was an option in our pattern 
recognition for such a modifier. Microchimerism has previously been described in MBD as a mechanism for 
development of autoimmunity40–44, graft-versus-leukemia effect60, and the mechanism of birth order effect due to 
increased acquired tolerance of the mother in step with her parities and the number of her male partners40,61,62. 
Also, the specific type of microchimerism in MBD has been discussed in the light of tolerance related to the 
degree of tissue-type compatibility (HLA-match) between mother, offspring and father60,62. Microchimerism has 
furthermore been related to the pathophysiology of some types of solid cancer, e.g. breast cancer63.
Microchimeristic susceptibility could be one mechanism behind anticipation, seen in the accumulation of sus-
ceptibility in the pedigree with increased genomic diversity in “the genomic landscape” down through the genera-
tions. Anticipation can be interpreted as a process that enhances the expression of the susceptibility. It is fascinating 
that the model also suggests a strategy for loss of susceptibility and thereby a delicate balance between genomic 
accumulation and depletion, so that affected families after a number of generations will not be overloaded with sus-
ceptibility. Anticipation produces an increased number of high-malignant diseases, especially in younger patients. 
ALL, having a high frequency in the inbred Faroes material (Table 1), is such an example with a very high mortality 
if untreated. In such cases, death leads to depletion of susceptibility in the population before and during fertile life.
The familial clustering of HL, seen in the present study (cf. Results, co- and contravariations) has previously 
been reported18 and ascribed to familial HLA-association12. Also, the modest risk of familial NHL seen in the 
present study (percentage of familial FL and DLBCL below the percentage of FL and DLBCL reported by the 
Cancer Registries, Table 1) has been described7. Comparing the findings in the Faroese family (related parents) 
with the families with MBD in Norway and Denmark (unrelated parents), HL and DLBCL have the highest 
percentage in the Faroese family where both parents due to inbreeding theoretically can transfer interfering 
susceptibility52.
In conclusion, the model suggested is an operational interaction between parental genomic imprinting of 
susceptibility genes and mother-son microchimerism. Theoretically, the intensity of the mother-son microchi-
merism depends on the tissue-type compatibility among mother, sons and the father. This may well explain why 
the segregation has been observed to be tardive with related parents, and immediate (from parent to offspring) 
with unrelated parents. The model explains the male predominance, the unique pathway 2 in the segregation of 
susceptibility to chronic lymphocytic leukemia, and draws attention to the relevance of growth factor genes for 
monoclonal expansion.
Data Availability
Data are stored at the National Norwegian Cancer Registry, Ullernchausseen 64, NO 0379, Oslo, Norway, att. Dr. 
Tom Børge Johannesen.
References
 1. Houlston, R. S. et al. Causation of chronic lymphocytic leukaemia, insight from familial disease. Leukemia Res. 27, 871–876 (2003).
 2. Marti, G. E. et al. B-cell monoclonal lymphocytosis and B-cell, abnormalities in the setting of familial B-cell CLL. Cytometry B, Clin. 
Cytom. 52, 1–12 (2003).
 3. Goldin, L. R. et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 100, 1902–1908 (2004).
1 1Scientific RepoRts |          (2019) 9:2444  | https://doi.org/10.1038/s41598-019-38879-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
 4. Rumi, E., Passamonti, F. & Della Porta, M. G. Familial chronic myeloproliferative disorders, clinical phenotype and evidence of 
disease anticipation. J. Clin. Oncol. 25, 5630–5635 (2007).
 5. Speedy, H. E., Sava, G. & Houlston, R. S. Inherited susceptibility to CLL. Adv. Exp. Med. Biol. 792, 293–308 (2013).
 6. Morgan, G. J. et al. Inherited genetic susceptibility to multiple myeloma. Leukemia 28, 518–524 (2014).
 7. Cerhan, J. R. & Slager, S. L. Familial predisposition and genetic risk factors for lymphoma. Blood 126, 2265–2273 (2015).
 8. Cousar, J. B. Hematopoietic-lymphoid neoplasms, principles of diagnosis. In: Greer, J. P., Foerster, J., Lukens, J. N. Rogers, G. M. 
Paraskevas, F. & Glader, B. (editors.) Wintrobe’s Clinical Hematology. Lippincott Williams & Wilkins Publ., pp. 1913–1915 (2004).
 9. Jan, M. & Majeti, R. Clonal evolution of acute leukemia genomes. Oncogene 32, 135–140 (2013).
 10. Conde, L. et al. Genome-wide association study of follicular lymphoma identifies a risk focus at 6p21.3. Nat. Genet 42, 661–664 
(2010).
 11. Crowther-Swanepoel, D. et al. Common variants at 2q37, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia 
risk. Nat. Genet. 42, 132–136 (2010).
 12. Enciso-Mora, V. et al. A genome-wide association study of Hodgkin’s lymphoma identifies new susceptibility loci at 2p16.1(REL), 
8q24.21 and 10p14(GATA3). Nat. Genet 42, 1126–1130 (2010).
 13. Slager, S. L., Caporaso, N. E., de Sanjose, S. & Goldin, L. R. Genetic susceptibility to chronic lymphocytic leukemia. Semin. Hematol. 
50, 296–302 (2013).
 14. Speedy, H. E. et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat. 
Genet. 46, 56–60 (2014).
 15. Skibola, C. F. et al. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA-region. 
Am. J. Hum. Genet. 95, 462–471 (2014).
 16. Perez-Andreu, V. et al. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young 
adults. Blood 125, 680–686 (2015).
 17. Berndt, S. I. et al. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat. 
Com. 7, https://doi.org/10.1038/ncomms10933 (2016).
 18. Thompson, E. A. Pedigree analysis of Hodgkin’s disease in a Newfoundland genealogy. Ann. Hum. Genet. 45, 279–292 (1981).
 19. Jønsson, V. et al. CLL family “pedigree 14” revisited: 1947 – 2004. Leukemia 19, 1025–1028 (2005).
 20. Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A. & Skolnick, M. H. Systematic population-based assessment of cancer risk in 
first-degree relatives of cancer probands. J. Natl. Cancer Inst. 86, 1600–1608 (1994).
 21. Amundadottir, L. T. et al. Cancer as a complex phenotype, pattern of cancer distribution within and beyond the nuclear family. PLoS 
Med. https://doi.org/10.1371/journal.pmed.0010065 (2004).
 22. Goldin, L. R., Pfeiffer, R. M., Li, X. & Hemminki, K. Familial risk of lymphoproliferative tumors in families of patients with chronic 
lymphocytic leukemia, results from the Swedish Family-Cancer Data Base. Blood 104, 1850–1854 (2004).
 23. Wang, S. S. et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL), a pooled analysis of 
10211 cases and 11905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 109, 3479–3488 
(2007).
 24. Landgren, O. et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with 
monoclonal gammopathy of undetermined significance in Sweden. Blood 114, 791–795 (2009).
 25. Emery, A. E. H. Parental age and birth order. In: Emery, A. E. H. (editor) Methodology in medical genetics, 2nd Edition. Churchill 
Livingstone. pp. 40–53 (1986).
 26. http://www.snomed.org.
 27. http://www.icd10data.com.
 28. http://www.progeny/software/genetics.com.
 29. Statistics Faroe Islands, http://www.hagstova.fo.
 30. Genetic Biobank, Ilegusanid, http://www.biobank.gov.fo.
 31. Olsen, S. F. & Joensen, H. D. High liveborn birth weights in the Faroese, a comparison between birth weights in the Faroese and in 
Denmark. J. Epidemiol. Community Health 39, 27–32 (1985).
 32. Norwegian Institute of Public Health, http://www.folkehelseinstitut.no/hn/statistikk (birth and pregnancy statistics).
 33. Statistics Denmark, http://www.statistikbanken.dk (population and birth).
 34. Report from the Norwegian Cancer Registry, http://www.kreftregisteret.no/registries/cancer statistics.
 35. Danish Cancer Registry, http://www.nordcan.dk.
 36. LYFO, D Lymphoma Group, http://www.lymphoma.dk.
 37. Sneath P. H. A. & Sokal R. R. Numerical Taxonomy, the Principles and Practice of Numerical Classification. San Francisco, W.H. 
Freeman and Comp. Publ., pp. 28–29 (1973).
 38. Bishop, C. M. Pattern recognition and machine learning, graphical models. Heidelberg, Springer Publ., pp. 359–418 (2006).
 39. Hartwell, L. H., et al. Genomic imprinting, parental origin affects the expression of some genes in mammals. In: Genetics, from 
genes to genomes, chapter 11, the eukaryotic chromosome. Boston, McGraw-Hill Comp., pp. 408–410 (2000).
 40. Tanaka, A., Lindor, K., Ansari, A. & Gershwin, M. E. Fetal microchimerisms in the mother, immunologic implications. Liver Transpl. 
6, 138–143 (2000).
 41. Nelson, J. L. Pregnancy and microchimerism in autoimmune disease, protector or insurgent? Arthr. Rheum. 46, 291–297 (2001).
 42. Nelson, J. L. Microchimerism in health and disease. Autoimmunity 36, 5–9 (2003).
 43. Adams, K. M. & Gadi, V. K. Autoimmunity in CLL, grave consequences of gravidity. Leuk.Lymphoma 47, 1445–1446 (2006).
 44. Adams, K., Zhan, Y., Stevens, A. & Nelson, J. L. The changing maternal “self ” hypothesis: A mechanism for maternal tolerance of the 
fetus. Placenta 28, 378–382 (2007).
 45. Molica, S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk. Lymphoma 47, 1477–1480 
(2006).
 46. Catovsky, D., Wade, R. & Else, M. The clinical significance of patients’ sex in chronic lymphocytic leukemia. Hematologica 99, 
1088–1094 (2014).
 47. Gentile, M. et al. Italian external multicentric validation of the MD Anderson Camcer Center monogram and prognostic index for 
chronic lymphocytic leukemia patients, analysis of 1502 cases. Br. J. Haematol 167, 224–232 (2014).
 48. Pflug, N. et al. Development of comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 124, 49–62 
(2014).
 49. Eckersley-Maslin, M. A. & Spector, D. L. Random monoallelic expression, regulating gene expression one allele at a time. Trends 
Genet. 30, 237–244 (2014).
 50. Ubeda, F. & Haig, D. Sex-specific meiotic drive and selection at an imprinted locus. Genetics 167, 2083–2095 (2004).
 51. Ubeda, F. & Haig, D. On the evolutionary stability of Mendelian segregation. Genetics 170, 1345–1357 (2005).
 52. Sasaki, H. & Matsui, Y. Epigenetic events in mammalian germ-cell development, reprogramming and beyond. Nat. Genet. 9, 
129–140 (2008).
 53. Jønsson, V. et al. Familial chronic lymphocytic leukemia in Norway and Denmark, comments on pleiotropy and birth order. In Vivo 
24, 85–96 (2010).
 54. Cassidy, S. B. & Driscoll, D. J. Prader-Willi syndrome. Eur. J. Hum. Genet. 17, 3–13 (2009).
1 2Scientific RepoRts |          (2019) 9:2444  | https://doi.org/10.1038/s41598-019-38879-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
 55. Hedström, G., Peterson, S., Berglund, M., Jerkeman, M. & Enblad, G. Male gender is an adverse risk factor only in young patients 
with diffuse large B-cell lymphoma, a Swedish population-based study. Acta Oncol. 54, 924–932 (2015).
 56. Roman, E. et al. Childhood lymphoblastic leukaemia and and birthweight, insight from pooled analysis of case-control data from 
Germany, the United Kingdom and the United States. Eur. J. Cancer 49, 1437–1447 (2013).
 57. O’Neill, K. A. et al. Infant birthweight and risk of childhood cancer, international population-based case control studies of 40 000 
cases. Int. J. Epidemiol. 44, 153–168 (2015).
 58. Hartl, D. L. Modifier theory and meiotic drive. Theor. Popul. Biol. 7, 168–174 (1975).
 59. Reik, W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447, 425–432 (2007).
 60. Van Rood, J. J., Scaradavou, A. & Stevens, C. E. Indirect evidence that maternal microchimerism in cord blood mediates a graft-
versus-leukemia effect in cord blood transplantation. Proc. Natl. Acad. Sci. USA 109, 2509–2514 (2012).
 61. Bianch, D. W. & Roberts, E. Fetomaternal cell trafficking, a story that begins with prenatal diagnosis and may end with stem cell 
therapy. J. Pediatr. Surg. 42, 12–18 (2007).
 62. Dawe, G. S., Tan, X. W. & Xiao, Z. C. Cell migration from baby to mother. Cell Adh. Migr. 1, 19–27 (2007).
 63. Gadi, V. K. Fetal microchimerism in breast from women with and without breast cancer. Breast Cancer Res. Treat. 121, 241–244 
(2010).
Acknowledgements
The study was undertaken in accordance with the Declaration of Helsinki. We thank the Genetics Resource 
Centre, Ministry of Health and Social Service, Government of the Faroe Islands for permission to do the study 
and for access to data, (record no. July 18, October 12, 2007) and the Norwegian Data Inspectorate (record no. 
07/00254-2), the Social and Health Directorate in Oslo (record no. 07/324), and the Regional Committee for 
Medical and Health Research Ethics, South-East Norway (record. S-06353b), the Royal Danish Archives and 
the Provincial Archives of Zealand (record no. 2000-441-0023), the Danish Data Protection Agency (record no. 
2000-41-0184), the Danish Scientific-Ethical Committees (record no. 01-224/01), and the Danish Board of Health 
(record no. 123-63-2000) for approving the study. One of us, Viggo Jønsson, received the Oslo University Travel 
Fund for travel to the Faroe Islands in connection with the present study.
Author Contributions
Viggo Jønsson, Haneef Awan and Neil Deaton Jones wrote the main manuscript text. All authors reviewed the 
manuscript. Haneef Awan did the bulk data processing and administrated the pedigrees. Neil Deaton Jones 
supervised the data processing and the interpretation of data. Tom Børge Johannesen cross-checked the family of 
each patient. Bjarni á Steig administrated the Faroese patient registry and guided the cross-check of the Faroese 
medical files. Gudrid Andorsdottir provided the pedigree of the inbred Faroese family. Geir E. Tjønnfjord 
participated in the interpretation of data.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
